Loading
A phase 2 trial of Trastuzumab duocarmazine in Endometrial cancer, run by Byondis B.V., completed.
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma is a phase 2 interventional study registered as NCT04205630 by Byondis B.V., with 64 participants recorded, started 2020-05-28 and reaching its primary completion in 2023-01-26. Interventions recorded: SYD985. Conditions recorded: Endometrial Cancer.
Linked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
64 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication
Source95% CI 11.6 to 20.5; Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication
Source95% CI 4.0 to 7.6; Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication
SourceShares Byondis, Trastuzumab duocarmazine and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.